Trial Profile
A Long-term, Multicenter, Single-arm, Open-label Extension of the SERENADE Study, to Assess the Safety and Efficacy of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms SERENADE OL
- Sponsors Actelion Pharmaceuticals
- 12 Oct 2022 Status has been changed to discontinued.
- 07 Apr 2022 This trial has been discontinued in Romania, according to European Clinical Trials Database record.
- 05 Nov 2021 This trial has been discontinued in Bulgaria, according to European Clinical Trials Database record.